Gossamer Bio (NASDAQ:GOSS) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Monday morning, MarketBeat Ratings reports.

A number of other equities analysts have also weighed in on GOSS. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Wedbush reiterated a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. HC Wainwright reduced their price target on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Finally, Oppenheimer dropped their target price on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, March 5th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.43.

Gossamer Bio Trading Down 11.6%

Shares of GOSS opened at $0.37 on Monday. Gossamer Bio has a 12-month low of $0.33 and a 12-month high of $3.87. The stock has a market cap of $87.59 million, a P/E ratio of -0.50 and a beta of 2.09. The company has a 50-day moving average of $1.61 and a two-hundred day moving average of $2.43.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $7.53 million. Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. As a group, analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of Gossamer Bio during the second quarter worth about $26,000. Ciovacco Capital Management LLC purchased a new stake in shares of Gossamer Bio during the 3rd quarter valued at about $27,000. Banco BTG Pactual S.A. acquired a new position in Gossamer Bio during the 2nd quarter worth approximately $27,000. MMA Asset Management LLC acquired a new position in Gossamer Bio during the 4th quarter worth approximately $31,000. Finally, Soltis Investment Advisors LLC purchased a new position in Gossamer Bio in the 4th quarter worth approximately $31,000. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.